Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bumetanide add-on pilot study for behavioral symptoms in children and adolescents with tuberous sclerosis complex
NL-OMON45855Phase 2Completed
- Sponsor
- University Medical Center Utrecht
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bumetanide in tuberous sclerosis complex (TSC), sponsored by University Medical Center Utrecht. Primary endpoint: Change in Aberrant Behaviour Checklist-Irritability subscale score. Started Mar 2017; status: completed.
02
Drugs
bumetanide
03
Conditions
tuberous sclerosis complex (TSC)
Beyond the preview
Go deeper on NL-OMON45855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45855.